Ankyra Therapeutics, Inc
Clinical trials sponsored by Ankyra Therapeutics, Inc, explained in plain language.
-
New injection fights Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called tolododekin alfa (ANK-101) in people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumors to see if it is safe and tolerable. About 97 adults with various cancers, inclu…
Phase: PHASE1 • Sponsor: Ankyra Therapeutics, Inc • Aim: Disease control
Last updated May 26, 2026 06:01 UTC
-
New combo aims to shrink lung tumors in patients who stopped responding to standard care
Disease control Recruiting nowThis early-stage study tests a new drug called tolododekin alfa combined with an immunotherapy for people with advanced non-small cell lung cancer. About 60 participants will join, including those whose cancer worsened after standard treatments and those who have not yet been tre…
Phase: PHASE1 • Sponsor: Ankyra Therapeutics, Inc • Aim: Disease control
Last updated May 26, 2026 05:49 UTC